DelveInsight Business Research LLP

DelveInsight’s, “Obesity Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Key Highlights from the Obesity Market Report

• The Key Companies working in Obesity pipeline include Aardvark, Adocia, Agentix AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group AstraZeneca, and many others.
• The Key Therapies working in Obesity pipeline include Semaglutide, Tirzepatide, Tesomet, RZL-012, EMP16, ZP 8396, and many others 

Learn more about the key trends and developments driving the market growth @ Obesity Pipeline 

Obesity Overview

Obesity is recognized as a chronic or noncommunicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body. Unwanted body weight gain leading to obesity and overweight has become the main driver of the global rise in non-communicable diseases; therefore, it is considered a noncommunicable disease. Because of the psychological and social stigma associated with being overweight and obese, those affected are also vulnerable to discrimination in their personal and work lives, low self-esteem, and depression. Childhood obesity results in the same comorbidities as obesity, with premature onset or greater likelihood in adulthood. The medical and psychological sequel of obesity contributes to a major threat to the socioeconomic healthcare burden, which is striking.

Obesity Companies

There are approx. 100+ key companies that are developing therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

Phases of Obesity Companies

DelveInsight’s report covers around 130+ Obesity products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 Molecule Type

Obesity Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Obesity Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obesity Key Companies 

• Novo Nordisk
• Eli Lilly and Company
• Eurofarma Laboratorios S.A. 
• And many others 

Obesity Key Therapies

• Semaglutide oral
• Tirzepatide
• Sibutramine/Topiramate 
• And many others.

Discover more about therapies set to grab major market share @ Obesity Pipeline Report 

Table of Contents

Learn more about the report offerings @ Obesity Pipeline 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services